RETA(Delisted)
Reata PharmaceuticalsยทNASDAQ
--
--(--)
RETA Profile
Reata Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company that develops novel therapeutics by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation
5320 Legacy Drive, Plano, TX 75024
--
Reata Pharmaceuticals, Inc. was founded in 2002 in Delaware, USA. The Company is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing product candidates that modulate the activity of key regulatory proteins involved in mitochondrial function, oxidative stress biology, inflammation, to address the medical needs of patients with a variety of serious or life-threatening diseases. The Company's lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules known as antioxidant inflammatory modulators, or AIM. Bardoxolone methyl is in Phase 2 clinical development of pulmonary hypertension, or polycyclic aromatic hydrocarbons, and treatment of pulmonary hypertension due to interstitial lung disease, or PH-ILD, each of which is a subset of pulmonary hypertension, or PH. Preliminary data on patients with PAH in their Phase 2 trial has been published at the October 2015 Chest Conference In addition, it has completed interactions with the U.S. Food and Drug Administration, or FDA, for this initial data, the FDA has endorsed its initiation of a Phase 3 clinical trial in patients with PAH and connective tissue disease, or CTD-PAH related programs.
